Chiron estimated lowered by Merrill

Chiron Corp. was maintained by Merrill Lynch analyst Eric Ende at a sell rating. However, because of ongoing problems with influenza manufacturing, Merrill lowered its 2005 EPS estimates to $1.15 from $1.30, which also is below company guidance of $1.20 to $1.45. Merrill also noted the FDA is asking for an additional clinical trial before it approves Pulmoniq for lung transplants. Emeryville, Calif.-based Chiron develops blood testing therapeutics, vaccines and other biopharmaceuticals. Chiron shares Friday lost $1.24, or 3.33%, to $36.03 on volume of 2.3 million shares versus the three-month running average of 1.2 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.